Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has presented important data from its ATH434-201 Phase 2 clinical trial at the 150th Annual Meeting of the American Neurological Association (ANA) in Baltimore, USA. The trial focused on Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease. These results mark a significant milestone for Alterity as it moves closer to providing the first disease-modifying therapy for MSA.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on disease-modifying treatments for neurodegenerative diseases, has successfully raised A$20.0 million through a strategic placement to international and Australian professional investors.

Alterity Therapeutics Limited (ASX: ATH; NASDAQ: ATHE) has announced highly promising topline results from its open-label Phase 2 clinical trial (ATH434-202) evaluating ATH434 in patients with advanced Multiple System Atrophy (MSA). The findings reinforce the company’s position as a front-runner in developing disease-modifying therapies for neurodegenerative diseases.